Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Thrombocytosis 1Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Mesothelioma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Neutrophilic, Chronic 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Hypereosinophilic Syndrome 1Dendritic Cell Sarcoma, Interdigitating 1Acromesomelic dysplasia, Maroteaux type 1

Interventions

pevonedistat 1Vincristine 1Rituximab 1Prednisone 1Filgrastim 1Etoposide 1Doxorubicin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Acromesomelic dysplasia, Maroteaux type × pevonedistat × Clear all
NCT01415765 2019-12-17

MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Withdrawn
LymphoidSarcoma

Acromesomelic dysplasia, Maroteaux type, Lymphoma, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡